FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247185831> ?p ?o ?g. }

• W2247185831 abstract "In the last decade, different molecular subtypes of breast cancer have been proposed. Although displaying appreciable association with disease prognosis and the prognostic value of cytotoxic and endocrine therapeutic modalities, the subtypes seem to fail at completely explaining disease behavior and response to treatment. Molecules such as those of the cyclocooxigenase (COX) family, currently composed of three entities (COX 1, 2 and 3) have been shown to be associated with breast carcinogenesis, and the analysis of p53 expression in breast tumors may also offer some additional prognostic clues. Our study is aimed at assessing COX2 and p53 expression in these clinico-pathological surrogate subtypes, and to evaluate whether the expression of these molecules can help further explain the variability in prognosis still found within the clinico-pathological subtypes groups of breast cancer.A total of 183 breast cancer samples were obtained from women treated at the Womeńs Hospital of Campinas State University, Campinas, Brazil, between June 2008 and January 2011. Immunohistochemistry was performed to detect the expression of ER, PR, ki67, COX2, and p53 and the HER2 status of the 183 specimens was assessed using FISH. Two COX2 staining thresholds were used to define COX2 positivity: low threshold (LT): moderate and intense staining were considered positive; high-threshold (HT): only intense staining was considered positive.There was no trend in COX2 overexpression from Luminal A-like to Triple-negative subtypes. By contrast, p53 was expressed in roughly 67% of the Luminal A-like tumors, 50% of the Luminal B-like HER2 positive tumors, 60.9% of the Luminal B-like HER2 negative, approximately 82% of the HER2 positive (non-luminal) and 87% of the Triple-negative tumors (p for trends=0.06). There was a significantly higher proportion of COX2 positive (LT) tumors (66.9%) when p53 was also positive compared to when the tumor was negative for p53 (in which case only18.0% of the tumors were positive for COX2; p<0.001). Neither marker was found to be associated with patients' survival.There seems to be a positive association between the expressions of COX2 and p53. Otherwise, neither the expression of COX nor that of p53 was associated with clinico-pathological subtypes, tumor features and prognosis. It seems to be too early to elect the detection of COX2 using IHC as prognostic or predictive tool, but incipient evidence points toward a possible role for the marker." @default.
• W2247185831 created "2016-06-24" @default.
• W2247185831 creator A5004791534 @default.
• W2247185831 creator A5004942489 @default.
• W2247185831 creator A5020767138 @default.
• W2247185831 creator A5032032427 @default.
• W2247185831 creator A5034258728 @default.
• W2247185831 creator A5039442895 @default.
• W2247185831 creator A5048719369 @default.
• W2247185831 creator A5052514324 @default.
• W2247185831 creator A5079884393 @default.
• W2247185831 creator A5082429747 @default.
• W2247185831 creator A5084244095 @default.
• W2247185831 creator A5084997825 @default.
• W2247185831 date "2016-03-01" @default.
• W2247185831 modified "2023-10-02" @default.
• W2247185831 title "Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival." @default.
• W2247185831 cites W1851641788 @default.
• W2247185831 cites W1892496998 @default.
• W2247185831 cites W1971380257 @default.
• W2247185831 cites W1978503888 @default.
• W2247185831 cites W1983271078 @default.
• W2247185831 cites W1984609427 @default.
• W2247185831 cites W1987076210 @default.
• W2247185831 cites W1991484054 @default.
• W2247185831 cites W1999713892 @default.
• W2247185831 cites W2010728517 @default.
• W2247185831 cites W2014747631 @default.
• W2247185831 cites W2018714752 @default.
• W2247185831 cites W2019181314 @default.
• W2247185831 cites W2032720315 @default.
• W2247185831 cites W2042037797 @default.
• W2247185831 cites W2059316622 @default.
• W2247185831 cites W2079172279 @default.
• W2247185831 cites W2080452335 @default.
• W2247185831 cites W2085392306 @default.
• W2247185831 cites W2085664688 @default.
• W2247185831 cites W2094714308 @default.
• W2247185831 cites W2097255042 @default.
• W2247185831 cites W2098225187 @default.
• W2247185831 cites W2102916008 @default.
• W2247185831 cites W2113633750 @default.
• W2247185831 cites W2117775530 @default.
• W2247185831 cites W2125702566 @default.
• W2247185831 cites W2127057139 @default.
• W2247185831 cites W2131994307 @default.
• W2247185831 cites W2137853125 @default.
• W2247185831 cites W2143176313 @default.
• W2247185831 cites W2149296602 @default.
• W2247185831 cites W2157160375 @default.
• W2247185831 cites W2157706516 @default.
• W2247185831 cites W2158324531 @default.
• W2247185831 cites W2158915678 @default.
• W2247185831 cites W2161770015 @default.
• W2247185831 cites W2168067539 @default.
• W2247185831 cites W2200950281 @default.
• W2247185831 cites W2582743722 @default.
• W2247185831 cites W3140920236 @default.
• W2247185831 cites W93096170 @default.
• W2247185831 doi "https://doi.org/10.1016/j.acthis.2015.12.009" @default.
• W2247185831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26791786" @default.
• W2247185831 hasPublicationYear "2016" @default.
• W2247185831 type Work @default.
• W2247185831 sameAs 2247185831 @default.
• W2247185831 citedByCount "7" @default.
• W2247185831 countsByYear W22471858312017 @default.
• W2247185831 countsByYear W22471858312018 @default.
• W2247185831 countsByYear W22471858312019 @default.
• W2247185831 countsByYear W22471858312020 @default.
• W2247185831 countsByYear W22471858312022 @default.
• W2247185831 crossrefType "journal-article" @default.
• W2247185831 hasAuthorship W2247185831A5004791534 @default.
• W2247185831 hasAuthorship W2247185831A5004942489 @default.
• W2247185831 hasAuthorship W2247185831A5020767138 @default.
• W2247185831 hasAuthorship W2247185831A5032032427 @default.
• W2247185831 hasAuthorship W2247185831A5034258728 @default.
• W2247185831 hasAuthorship W2247185831A5039442895 @default.
• W2247185831 hasAuthorship W2247185831A5048719369 @default.
• W2247185831 hasAuthorship W2247185831A5052514324 @default.
• W2247185831 hasAuthorship W2247185831A5079884393 @default.
• W2247185831 hasAuthorship W2247185831A5082429747 @default.
• W2247185831 hasAuthorship W2247185831A5084244095 @default.
• W2247185831 hasAuthorship W2247185831A5084997825 @default.
• W2247185831 hasConcept C121608353 @default.
• W2247185831 hasConcept C126322002 @default.
• W2247185831 hasConcept C142724271 @default.
• W2247185831 hasConcept C143998085 @default.
• W2247185831 hasConcept C204232928 @default.
• W2247185831 hasConcept C207886595 @default.
• W2247185831 hasConcept C2780110267 @default.
• W2247185831 hasConcept C530470458 @default.
• W2247185831 hasConcept C555283112 @default.
• W2247185831 hasConcept C71924100 @default.
• W2247185831 hasConceptScore W2247185831C121608353 @default.
• W2247185831 hasConceptScore W2247185831C126322002 @default.
• W2247185831 hasConceptScore W2247185831C142724271 @default.
• W2247185831 hasConceptScore W2247185831C143998085 @default.
• W2247185831 hasConceptScore W2247185831C204232928 @default.
• W2247185831 hasConceptScore W2247185831C207886595 @default.
• W2247185831 hasConceptScore W2247185831C2780110267 @default.

• next